Google快讯 - lung cancer

	lung cancer 实时更新 ⋅ 2024年6月1日
	新闻
	Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ ... PR Newswire Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), commencing enrollment in 2023 in two Phase III ... 标记为不相关
	Subcutaneous Amivantamab Plus Lazertinib Maintains Efficacy With Improved Safety and ... ASCO Daily News In patients with refractory EGFR-mutated advanced non–small cell lung cancer (NSCLC), subcutaneous amivantamab plus lazertinib was noninferior to ... 标记为不相关
	Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with ... - TradingView TradingView ... Lung Cancer (mNSCLC). Jun 1, 202406:59 PDT. Initial data from the ongoing ... https://www.cancer.org/cancer/types/lung-cancer.html. Accessed May 14 ... 标记为不相关
查看更多结果 | 修改此快讯

您收到此电子邮件是因为您订阅了Google快讯。 退订 | 查看您所有的快讯

以RSS Feed的形式接收此快讯

发送反馈